T-CELL LYMPHOPROLIFERATIVE DISORDER FOLLOWING MYCOPHENOLATE TREATMENT FOR MYASTHENIA GRAVIS
T-CELL LYMPHOPROLIFERATIVE DISORDER FOLLOWING MYCOPHENOLATE TREATMENT FOR MYASTHENIA GRAVIS
复制标题
DOI：
10.1002/mus.21306
复制
发表时间：
2009-06-01
期刊：
影响因子：
3.4
通讯作者：
Josephson, S. Andrew
中科院分区：
文献类型：
--
作者：
Dubal, Dena B.;Mueller, Sabine;Josephson, S. Andrew
免疫抑制治疗在包括重症肌无力在内的许多疾病的管理中至关重要。吗替麦考酚酯是一种广泛使用的口服免疫抑制剂，与同类药物相比，其不良反应较少。我们报告的情况下，病人谁开发T细胞淋巴组织增生性病变后，长期治疗霉酚酸酯和泼尼松重症肌无力。停止治疗后病变消退。这个病例突出了一种常用药物的严重并发症。肌肉神经39：849-850，2009
Immunosuppressive therapies are critical in the management of numerous conditions including myasthenia gravis. Mycophenolate mofetil is a widely used, oral immunosuppressive agent that is considered to have few adverse effects compared with similar drugs. We report the case of a patient who developed T-cell lymphoproliferative lesions following long-term treatment with mycophenolate mofetil and prednisone for myasthenia gravis. The lesions resolved following cessation of the treatment. This case highlights a serious complication of a commonly used drug. Muscle Nerve 39: 849-850, 2009